Skip to main content

2022

2022-08-09
ANOTHER AGREEMENT IN PLACE AND PATIENT ENROLLMENT ONGOING IN THE NORTH AMERICAN PHASE 3 STUDY
2022-08-04
STOCKHOLM, August 4[th], 2022, Moberg Pharma AB (OMX: MOB) has signed a distribution agreement with Padagis Israel Agencies Ltd. for MOB-015 in Israel and the Palestinian territories. Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.
2022-06-30
STOCKHOLM, June 30[th], 2022, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 100,859,335 due to the completion of the previously announced rights issue, the previously announced directed issue to certain guarantors in the rights issue and the previously announced issue of class C shares, which subsequently have been repurchased and converted to common shares, intended to ensure fulfilment of commitments under incentive programmes.
2022-06-08
STOCKHOLM, 8 June 2022. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) has today resolved on a directed new issue of 536,952 ordinary shares to the guarantors in the rights issue of ordinary shares resolved upon by the Board of Directors on 8 April 2022 and approved by the Extraordinary General Meeting on 3 May 2022 (the “Rights Issue”) who have chosen to receive their guarantee commission in the form of newly issued ordinary shares in Moberg Pharma (the "Remuneration Issue"). The subscription price in the Remuneration Issue corresponds to the subscription price in the Rights Issue, SEK 2.30 per ordinary share, and payment is made by set-off of claims.
2022-06-08
STOCKHOLM, June 8[th] 2022. Moberg Pharma AB (OMX: MOB) announced that the board of directors exercises authorizations to issue and repurchase C-shares, and converts C-shares to common shares, to secure the company’s commitments under incentive programme.
2022-05-31
STOCKHOLM, 31 May 2022. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) today announces the outcome of the fully guaranteed rights issue of ordinary shares with preferential rights for Moberg Pharma’s shareholders (the “Rights Issue”) which was resolved upon by the Board of Directors on 8 April 2022 and approved by an extraordinary general meeting on 3 May 2022. In total, 24,305,220 ordinary shares were subscribed for with support of subscription rights, corresponding to approximately 46.3 percent of the Rights Issue. 775,636 ordinary shares, corresponding to approximately 1.5 percent of the Rights Issue, have been allotted to persons who have subscribed for ordinary shares without support of subscription rights. Therefore, the issue guarantors are allotted approximately 52.2 percent of the Rights Issue. Moberg Pharma will receive approximately SEK 120.8 million before deduction for transaction costs.
2022-05-16
STOCKHOLM, May 16[th], 2022. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.
2022-05-11
Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) announces that the prospectus relating to the Company’s rights issue of ordinary shares (the “Rights Issue”) has been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company’s website www.mobergpharma.se/investerare/prospekt and will also be available at the Swedish Financial Supervisory Authority’s website www.fi.se.
2022-05-10
EUROPEAN MARKETING AUTHORIZATION APPLICATION SUBMITTED AND NORTH AMERICAN PHASE 3 STUDY STARTED
2022-05-10
Moberg Pharma AB (OMX: MOB) today announced that patient enrollment has started in the North American Phase 3 study for MOB-015 (nail fungus treatment).
2022-05-03
STOCKHOLM, 3 May 2022. Moberg Pharma AB (publ)’s (OMX: MOB) (“Moberg Pharma” or the “Company”) Extraordinary General Meeting took place today. The Extraordinary General Meeting resolved as set out below.
2022-04-29
STOCKHOLM, April 29[th], 2022, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 46,681,123 due to the completion of the previously announced exercise of warrants of series 2020:1.
2022-04-12

Moberg Pharma´s Annual Report for 2021 has been published and is available on www.mobergpharma.se

2022-04-12
Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426, (the “Company”) are hereby convened to the Annual General Meeting on 16 May 2022.
2022-04-08
Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426 (the “Company”), are hereby convened to the Extraordinary General Meeting on 3 May 2022.
2022-04-08
STOCKHOLM, 8 April 2022. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or “the Company”) has today resolved to carry out a fully guaranteed issue of new ordinary shares with preferential rights for existing shareholders (the “Rights Issue”) of approximately SEK 121 million before transaction costs. The Rights Issue is conditional upon approval at an extraordinary general meeting (the “Extraordinary General Meeting”). The net proceeds will be used for registration activities and clinical work for MOB-015.
2022-03-31
STOCKHOLM, March 31[th], 2022. The exercise period for Moberg Pharma AB's (publ)'s ("Moberg Pharma" or the "Company") warrants of series 2020:1 ended 29 March 2022. In total, 2,339,396 warrants of series 2020:1 were exercised for subscription of in total 1,169,698 ordinary shares, corresponding to a subscription rate of approximately 10.1 percent. Moberg Pharma will thereby receive proceeds of approximately SEK 7,568,000 before issue costs.
2022-03-28
Moberg Pharma AB (publ) have submitted its marketing authorization application for MOB-015 (nail fungus treatment). The company has submitted the application in Europe through the decentralized procedure, and market approval is expected in 2023.
2022-03-25
STOCKHOLM, March 25[th], 2022. Today, 25 March 2022, is the last day for trading in Moberg Pharma AB's (publ)'s ("Moberg Pharma" or the "Company") warrants of series 2020:1. The exercise period runs until 29 March 2022.
2022-03-18
Moberg Pharma AB (publ) has submitted regulatory filing for the next clinical Phase 3 study for MOB-015 (nail fungus treatment) to the U.S. Food and Drug Administration (FDA).
2022-03-16
STOCKHOLM, March 16[th], 2022. Today the exercise period for Moberg Pharma AB (publ)'s ("Moberg Pharma" or the "Company") warrants of series 2020:1 begins. The exercise period runs during the period from and including 16 March 2022 up to and including 29 March 2022. The last day for trading in warrants of series 2020:1 on Nasdaq Stockholm is 25 March 2022.
2022-03-14
STOCKHOLM, March 14[th], 2022. Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") hereby announces that the subscription price for warrants of series 2020:1 is SEK 6.47. The exercise period begins on 16 March 2022 and runs until 29 March 2022. The last day for trading in warrants of series 2020:1 on Nasdaq Stockholm is 25 March 2022.
2022-02-08
THE MEDICAL PRODUCTS AGENCY IN SWEDEN WILL BE REFERENCE MEMBER STATE IN MOBERG PHARMA´S EUROPEAN REGISTRATION APPLICATION  
2022-02-01
STOCKHOLM, February 1[st], 2022. Moberg Pharma AB (OMX: MOB) announces that the company’s Nomination Committee has decided to present the following proposal to the Annual General Meeting 2022.